Whether you have eczema, poison ivy exposure or minor skin irritation, dermatologists say these skin care products can help.

July 24, 2025 – The FDA has approved a new treatment as the first and only skin cream for a specific type of hand eczema that affects about 1 in every 10 people globally. The cream, sold under the ...

Sept 18 (Reuters) - The U.S. Food and Drug Administration has approved Incyte's (INCY.O), opens new tab eczema cream for children aged between 2 and 11 years, the company said on Thursday. Wilmington, ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA. The agency approved delgocitinib cream 2% (Anzupgo) for adults with moderate-to-severe CHE, ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) shares gained 1.5% in premarket trading Monday after the U.S. Food and Drug Administration (FDA) approved the company’s ZORYVE (roflumilast) cream 0.05% for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Approximately 1.8 million children aged 2 to 5 years are ...

What Is Opzelura, and Why Does It Matter? Opzelura (ruxolitinib) is a prescription cream that helps reduce skin inflammation. It works by blocking certain proteins in the body called Janus kinases ...

Eczema typically refers to a skin condition that causes constant itching, redness, and dryness. For some people dealing with eczema, it can be an uphill fight. As much as there are numerous ...

Ruxolitinib cream was approved for moderate atopic dermatitis in non-immunocompromised patients aged 2 years and older. The phase 3 TRuE-AD3 study showed significant efficacy and safety in children ...

The US FDA has approved ruxolitinib (Opzelura) cream 1.5% for the short-term and noncontinuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in nonimmunocompromised children aged 2 ...